Stueland Katherine

GeneDx CEO Katherine Stueland sold 12,858 shares for $1,390,911.39 under 10b5-1 plan

Katherine Stueland, GeneDx CEO, executed 8 separate sales totaling 12,858 shares for $1,390,911.39 across a single trading date at prices ranging from $105.10 to $113.68. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-08-16, meaning the sales were scheduled and not discretionary. Post-transaction, Stueland retains 1,720 shares, representing an 88.2% reduction in her prior holding of 14,578 shares. The large position reduction warrants investor attention regarding executive confidence in the company's direction going forward.

GeneDx CEO Katherine Stueland sold 9,657 shares for $878,180.62 on 2025-07-01 under pre-arranged 10b5-1 plan

Katherine Stueland, Chief Executive Officer of GeneDx Holdings Corp. (WGS), executed 3 separate sales totaling 9,657 shares for $878,180.62 at prices ranging from $90.68 to $92.46 per share on July 1, 2025. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2024-08-16, meaning the sales were scheduled rather than discretionary. The sale reduced Stueland's holdings from 14,597 shares to 4,940 shares, representing a 66.2% reduction in her prior position. As a scheduled divestiture under a pre-arranged plan, this transaction does not reflect contemporaneous market judgment or timing discretion by the CEO.

CEO Katherine Stueland sold 46,594 shares for $4,175,816.57 via scheduled 10b5-1 plan on 2025-04-09, reducing holdings 96.4%.

Katherine Stueland, CEO of GeneDx Holdings Corp., executed 16 separate sales on 2025-04-09 under a pre-arranged 10b5-1 trading plan adopted on 2024-08-16, reducing her holdings from 48,314 shares to 1,720 shares (down 96.4%). The blended average sale price was $89.62 across a range spanning $81.16 to $97.24 per share, totaling $4,175,816.57. As a scheduled transaction, this represents an automatic execution rather than a discretionary trading decision. The dramatic reduction in CEO shareholding is notable in magnitude and concentration, though the pre-arranged nature and execution across multiple price points signal a structured, plan-based transaction rather than a spontaneous response to market conditions.

GeneDx CEO Katherine Stueland sold 51,420 shares for $4,858,118.95 via 4 separate sales on 2025-01-07 under 10b5-1 plan; retains 1,720 shares.

Katherine Stueland, Chief Executive Officer of GeneDx Holdings Corp., executed 4 separate sales totaling 51,420 shares for $4,858,118.95 at prices ranging from $93.34 to $96.39 on 2025-01-07. This transaction reduces her holdings from 53,140 shares to 1,720 shares, a reduction of 51,420 shares or 96.8% of pre-transaction holdings. The sales were executed pursuant to a 10b5-1 trading plan adopted on 2024-08-16, meaning the transactions follow a pre-arranged schedule rather than discretionary timing. As a scheduled disposition, this filing reflects contractual obligation rather than a real-time market or company-specific decision by the CEO.

CEO Katherine Stueland sold 18,006 shares for $1,407,686.35 on 2025-01-02 via pre-arranged 10b5-1 plan.

Katherine Stueland, Chief Executive Officer of GeneDx Holdings Corp., executed 6 separate sales totaling 18,006 shares for $1,407,686.35 at prices ranging from $75.47 to $80.47 per share on 2025-01-02. The sales reduced her holdings from 71,146 shares to 53,140 shares, a reduction of approximately 25.3%. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-08-16, meaning the trades were scheduled in advance rather than discretionary decisions made at the time of execution. The multiple tranches executed at ascending prices across a single trading day reflect the mechanics of a pre-planned divestiture. As a scheduled transaction under a Rule 10b5-1 plan, this activity does not carry timing-dependent interpretation.

CEO Katherine Stueland sold 45,415 shares across 13 transactions for $3,197,684.32 via scheduled 10b5-1 plan.

Katherine Stueland, CEO of GeneDx Holdings (WGS), executed 13 separate sales totaling 45,415 shares for $3,197,684.32 (blended average price $70.41) on November 15 and 18, 2024. The sales reduced her holdings from 105,426 shares to 60,011 shares, representing a 43.1% reduction in her pre-transaction position. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on August 16, 2024, meaning the sales were scheduled rather than discretionary decisions. The multi-day, multi-tranche execution at gradually rising prices during the November 15–18 window reflects the mechanics of a programmatic plan rather than a concentrated, opportunistic exit.